CD4 and infection: The prevalence of resistance to tenofovir reached 80% in individuals with TAMs, a result that is concerning and very much unexpected given that the tenofovir mutation Lys65Arg and TAMs are thought to be antagonistic to one another.17 Patients with TAMs tended to have lower CD4 counts than did patients without TAMs, which is consistent with longer duration of infection or faster disease progression.